Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SC262 · 1 trial · 2 indications
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| SC262 Plus Chemotherapy Regimen | EXPERIMENTAL | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262 |
| Name | Type | Description |
|---|---|---|
| SC262 | DRUG | SC262 is an allogeneic CAR -T cell therapy |
Inclusion Criteria: 1. Male or Female Subject aged 18-80 years at the time of signing the informed consent 2. Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including: * LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (includin...
SC262 is an investigational small molecule being studied for the treatment of relapsed or refractory Non-Hodgkin's Lymphoma, including Large B-cell Lymphoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
SC262 targets CD22, a cell surface protein expressed on B-cells. By targeting CD22, SC262 is designed to interfere with malignant B-cell activity in Non-Hodgkin's Lymphoma. It is being evaluated as a monotherapy in an uncontrolled, open-label Phase 1 trial.
SC262 is being developed by Sana Biotechnology, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol SANA. The company is conducting a Phase 1 clinical trial of SC262 in patients with relapsed or refractory Non-Hodgkin's Lymphoma.
SC262 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 6 patients in the United States.
SC262 is being evaluated in a single Phase 1 clinical trial with the identifier NCT06285422, titled 'Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)'. The trial is active but not recruiting, enrolling 6 adult patients in the United States.